Articles written by Vandana Singh - Benzinga

Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test

Guardant Reveal test receives expanded Medicare coverage for colorectal cancer recurrence monitoring, enhancing revenue potential and clinical adoption.

Europe Drug Regulator Expands GSK's Jemperli/Chemo Combo To Adult Patients With Advanced Endometrial Cancer

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant trial results.

BrightSpring Health Divests Community Living Business For $850 Million To Focus On Core Activities

BrightSpring will sell its Community Living business to Sevita for $835M in a deal set to close in 2025, boosting operational focus and revenue growth projections.

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

FDA halts Atara's EBVALLO and ATA3219 trials over manufacturing issues. Atara eyes $60 million milestone from Pierre Fabre upon EBVALLO approval.

FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients

AstraZeneca's Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies, based on Phase 3 trial data.

Why Is Moderna Stock Trading Higher On Tuesday?

Moderna secures $590 million from HHS for mRNA flu vaccine development.

FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression

FDA approves Johnson & Johnson's Spravato nasal spray as a monotherapy for major depressive disorder, showing superior efficacy in clinical trials.

Justice Department Accuses Walgreens Of Violating Drug Laws In Opioid Epidemic, Ignored Red Flags In Opioid Crisis

The DOJ accuses Walgreens of dispensing unlawful opioid prescriptions and violating federal health laws, alleging the pharmacy chain contributed to the opioid crisis.

Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot

Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions.

EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases

Coya Therapeutics advances COYA 303 for inflammatory diseases, combining COYA 301 and GLP-1 RA for a synergistic anti-inflammatory effect.

FDA Warns Hologic Over BioZorb Manufacturing Violations

FDA issues warning to Hologic, citing manufacturing and safety violations for BioZorb devices. Patient safety risks and reporting failures highlighted

Teva Challenges Drug Price Law's Impact On Innovation, Generics

Teva Pharmaceuticals challenges the Inflation Reduction Act, arguing CMS's drug pricing policies harm generics, biosimilars, and innovation, disrupting healthcare balance.

UnitedHealth's Strong Member Loyalty Powers Analyst Growth Forecasts

UnitedHealth Q4 earnings beat EPS estimates at $6.81 but missed revenue projections. Analysts highlight growth potential in Medicare Advantage trends.

AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline

AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives and focusing on innovative cancer drugs.

Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.

FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation

Amgen's Lumakras treatment, combined with Vectibix, is FDA-approved for KRAS G12C-mutated colorectal cancer.

Goldman CEO David Solomon Receives $80 Million Retention Stock Award

Goldman Sachs awards $80 million retention RSUs to CEO David Solomon and COO John Waldron, emphasizing leadership stability, long-term value, and strategic priorities.

FDA Approves AstraZeneca's Calquence Combo Therapy For Untreated Mantle Cell Lymphoma

AstraZeneca's Calquence gains FDA approval for untreated mantle cell lymphoma, supported by data showing improved survival and reduced disease progression.

Novo Nordisk's Higher Dose Of Wegovy Shows Roughly 21% Weight Loss

Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and placebo over 72 weeks.

FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease

FDA approves Eli Lilly's Omvoh for Crohn's disease, showing strong Phase 3 results in clinical remission and intestinal healing over two years.